Skip to main content
Top
Published in: BMC Infectious Diseases 1/2023

Open Access 01-12-2023 | Case Report

Pseudomonas otitidis bacteremia in an immunocompromised patient with cellulitis: case report and literature review

Authors: Takeo Mori, Sadako Yoshizawa, Kageto Yamada, Takahiro Sato, Masakazu Sasaki, Yusuke Nakamura, Ukyo Gen, Hinako Murakami, Katsuhito Kashiwagi, Tadashi Maeda, Taito Miyazaki, Tetsuo Yamaguchi, Yoshihisa Urita, Yoshikazu Ishii, Kazuhiro Tateda

Published in: BMC Infectious Diseases | Issue 1/2023

Login to get access

Abstract

Background

Pseudomonas otitidis belongs to the genus Pseudomonas and causes various infections, including ear, skin, and soft tissue infections. P. otitidis has a unique susceptibility profile, being susceptible to penicillins and cephalosporins but resistant to carbapenems, due to the production of the metallo-β-lactamase called POM-1. This revealed genetic similarities with Pseudomonas aeruginosa, which can sometimes lead to misidentification.

Case presentation

We report the case of a 70-year-old Japanese male who developed cellulitis and bacteremia during chemotherapy for multiple myeloma. He was initially treated with meropenem, but blood culture later revealed gram-negative bacilli identified as P. otitidis using matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS). Carbapenem resistance was predicted from previous reports; therefore, we switched to dual therapy with levofloxacin and cefepime, and favorable treatment results were obtained.

Conclusion

This is the first reported case of P. otitidis cellulitis and bacteremia in an immunocompromised patient. Carbapenems are typically used in immunocompromised patients and P. otitidis is often resistant to it. However, its biochemical properties are similar to those of Pseudomonas aeruginosa; therefore, its accurate identification is critical. In the present study, we rapidly identified P. otitidis using MALDI-TOF MS and switched from carbapenems to an appropriate antimicrobial therapy, resulting in a successful outcome.
Literature
7.
go back to reference Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically Approved Standard. 10th ed. Wayne, PA, USA: CLSI; 2015. p. M07–A10. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically Approved Standard. 10th ed. Wayne, PA, USA: CLSI; 2015. p. M07–A10.
8.
go back to reference Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: twenty-sixth information supplement M100-S26. Wayne, PA, USA: CLSI; 2016. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: twenty-sixth information supplement M100-S26. Wayne, PA, USA: CLSI; 2016.
Metadata
Title
Pseudomonas otitidis bacteremia in an immunocompromised patient with cellulitis: case report and literature review
Authors
Takeo Mori
Sadako Yoshizawa
Kageto Yamada
Takahiro Sato
Masakazu Sasaki
Yusuke Nakamura
Ukyo Gen
Hinako Murakami
Katsuhito Kashiwagi
Tadashi Maeda
Taito Miyazaki
Tetsuo Yamaguchi
Yoshihisa Urita
Yoshikazu Ishii
Kazuhiro Tateda
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2023
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-023-08919-0

Other articles of this Issue 1/2023

BMC Infectious Diseases 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.